Abstract
Clinical evidence have shown SBRT to be a tolerable, efficacious, and promising non-invasive therapy. Randomized prospective studies comparing surgery vs. SBRT in early-stage lung cancer are proposed to further investigate the relative survival, quality of life, and cost characteristics of these treatment paradigms. Accreditation and dosimetry requirements were carefully vetted for RTOG SBRT trials. Advanced technologies introduced since have posed additional challenges. This study provides an overview of the quality requirements including those for the recently introduced technologies.
| Original language | English (US) |
|---|---|
| Title of host publication | World Congress on Medical Physics and Biomedical Engineering |
| Pages | 2284-2287 |
| Number of pages | 4 |
| DOIs | |
| State | Published - Apr 16 2013 |
| Event | World Congress on Medical Physics and Biomedical Engineering - Beijing, China Duration: May 26 2012 → May 31 2012 |
Publication series
| Name | IFMBE Proceedings |
|---|---|
| Volume | 39 IFMBE |
| ISSN (Print) | 1680-0737 |
Other
| Other | World Congress on Medical Physics and Biomedical Engineering |
|---|---|
| Country | China |
| City | Beijing |
| Period | 5/26/12 → 5/31/12 |
Fingerprint
Keywords
- NSCLC
- SBRT
- Surgery
- clinical trials
- quality
ASJC Scopus subject areas
- Bioengineering
- Biomedical Engineering
Cite this
Quality requirements for stereotactic body radiation therapy (SBRT) in multi-institutional clinical trials. / Xiao, Y.; Yin, F.; Kong, Feng Ming; Yue, J.; Galvin, J.
World Congress on Medical Physics and Biomedical Engineering. 2013. p. 2284-2287 (IFMBE Proceedings; Vol. 39 IFMBE).Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
}
TY - GEN
T1 - Quality requirements for stereotactic body radiation therapy (SBRT) in multi-institutional clinical trials
AU - Xiao, Y.
AU - Yin, F.
AU - Kong, Feng Ming
AU - Yue, J.
AU - Galvin, J.
PY - 2013/4/16
Y1 - 2013/4/16
N2 - Clinical evidence have shown SBRT to be a tolerable, efficacious, and promising non-invasive therapy. Randomized prospective studies comparing surgery vs. SBRT in early-stage lung cancer are proposed to further investigate the relative survival, quality of life, and cost characteristics of these treatment paradigms. Accreditation and dosimetry requirements were carefully vetted for RTOG SBRT trials. Advanced technologies introduced since have posed additional challenges. This study provides an overview of the quality requirements including those for the recently introduced technologies.
AB - Clinical evidence have shown SBRT to be a tolerable, efficacious, and promising non-invasive therapy. Randomized prospective studies comparing surgery vs. SBRT in early-stage lung cancer are proposed to further investigate the relative survival, quality of life, and cost characteristics of these treatment paradigms. Accreditation and dosimetry requirements were carefully vetted for RTOG SBRT trials. Advanced technologies introduced since have posed additional challenges. This study provides an overview of the quality requirements including those for the recently introduced technologies.
KW - NSCLC
KW - SBRT
KW - Surgery
KW - clinical trials
KW - quality
UR - http://www.scopus.com/inward/record.url?scp=84876020076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876020076&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-29305-4_599
DO - 10.1007/978-3-642-29305-4_599
M3 - Conference contribution
AN - SCOPUS:84876020076
SN - 9783642293047
T3 - IFMBE Proceedings
SP - 2284
EP - 2287
BT - World Congress on Medical Physics and Biomedical Engineering
ER -